research focus

The VIA programme is designed to support clinical research in cystic fibrosis (CF) and applications for clinical research projects will be considered across the entire field of CF.

Clinical research relates to patient-oriented research - interventional studies, epidemiologic studies, outcomes studies and translational studies.

Please note that any research studies related to Vertex products (either currently on the market or under clinical development) or those focused on non-clinical research will be excluded.

application process

The application process will be as follows:


Applicant downloads LOI form from VIA website


Applicant submits completed LOI via email


VIA Committee reviews submitted LOIs against selection criteria


VIA Committee shortlists approximately 10 LOIs compliant with selection criteria to proceed to phase 2 of the application process and the submission of a full proposal


VIA Committee invites shortlisted LOI applicants to submit an FP. Guidelines will be provided to the shortlisted applicants


Applicant submits FP as a Word document via email


VIA Committee engages with external reviewers to review FPs against selection criteria


VIA Committee selects 1 - 3 FPs for a grant award, with a combined total value up to
EUR 500,000


VIA Committee provides feedback to all FP applicants



VIA Committee announces details of selected project(s) awarded a grant



Applications are welcome from medical or research centres with a demonstrated record of research and achievement in CF.

Applications are welcome from single centres or multi-centres participating in collaborative research. For all applications, however, a lead investigator centre needs to be nominated.

Applications will be eligible from centres in all countries (except those from the US and Canada) provided the lead investigator centre is from one of the following countries:

  • Australia
  • Austria
  • Belgium
  • Denmark
  • France
  • Germany
  • Greece
  • Italy
  • Israel
  • Ireland
  • The Netherlands
  • New Zealand
  • Norway
  • Portugal
  • Spain
  • Sweden
  • Switzerland
  • UK

Applications from centres in countries that are not listed above (other than centres in the US and Canada) are most welcome provided that they partner with a centre from one of the above listed countries which will act as the lead centre.

Applications that include centres from the US or Canada are not eligible for funding. Applicants should be able to demonstrate that the proposed research will be led by an individual (or individuals) with an established career interest in CF and that they hold an MD, PhD or equivalent degree at the time of the application. Applications are also welcomed from early career investigators.

Applicants should be able to complete the proposed research within a 2-year award period, providing interim 6-month evidence of progress to the VIA Committee. The VIA Committee will confirm the reporting requirements at the selection of the final project. Applications should also show the ability to follow local and international requirements (ICH).

All applications need to be supported by the institution hosting the research. An authorised signatory will be required for the submission of the Letter of Intent application.

Grants awarded under this programme should not duplicate funding from other government, non-governmental or industry sources. In addition, applications will not be accepted from members or centres of members of the VIA Committee.

selection criteria

The communication, review and selection of applicants and their applications is undertaken by the VIA Committee. Vertex remains independent of the entire application and selection process and has no communication with applicants until the final candidates are selected by the VIA Committee.

Applications will be reviewed and scored by the VIA Committee using a score card according to the following selection criteria:

A. Quality of proposal idea (30% weighting)

Innovation of research; feasibility of research; alignment to the VIA programme's research focus

B. Ability of the PI/Group to deliver the project (30% weighting)

Experience and record of executing research projects of comparable scope, expertise, time, budget; experience and record of research centre in therapy area; quality and availability of resources; adherence to ethical principles; design, execution and monitoring of the research by the principal investigator; reasonable approach to budget

C. Impact of project on understanding or treatment of CF (40% weighting)

dates & deadlines

15 August 2016

Letter of Intent (LOI) application period opens

11 November 2016

LOI application period closes (24:00 CET)

19 December 2016

Communication to shortlisted LOI applicants and circulation of Full Proposal (FP) application form

13 March 2017

FP application period closes (24:00 CET)

June 2017

Communication to successful applicant(s)


Timelines may change at the discretion of the VIA Secretariat and all applicants/potential applicants will be notified accordingly.

contact us

contact us

Should you have any queries regarding the VIA programme or the process of submitting a proposal, please complete the online form below.